Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Journal of Cancer Research and Clinical Oncology

• Publication date

  2022-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00432-022-04396-1PMID 36318332PMCID PMC11796864
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis

  2021cited by this paper
• Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis.

  2021cited by this paper
• Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.

  2021cited by this paper
• Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status

  2021cited by this paper
• Clinical value of upfront cranial radiotherapy in osimertinib-treated EGFR-mutant non-small-cell lung cancer with brain metastases.

  2021cited by this paper
• Efficacy and Safety of Intrathecal Pemetrexed Combined with Dexamethasone for Treating TKI-failed Leptomeningeal Metastases from EGFR-mutant NSCLC-A Prospective Open-label Single-arm Phase I/II Clinical Trial (unique identifier: ChiCTR1800016615).

  2021cited by this paper
• Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

  2021influential reference
• Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status.

  2020cited by this paper
• Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer.

  2020cited by this paper
• CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer.

  2020cited by this paper
• Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI

  2020cited by this paper
• A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.

  2020cited by this paper
• The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non‐small‐cell lung cancer‐a retrospective study from one single cancer institute

  2019cited by this paper
• Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications

  2019cited by this paper
• Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis

  2019cited by this paper
• Osimertinib for patients with leptomeningeal metastases associated with epidermal growth factor receptor T790M positive advanced NSCLC: the AURA LM analysis.

  2019cited by this paper
• Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

  2018influential reference
• EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.

  2018cited by this paper
• Leptomeningeal metastases in non-small-cell lung cancer.

  2018cited by this paper
• CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

  2018cited by this paper
• Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.

  2018cited by this paper
• Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

  2018cited by this paper
• EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib

  2017cited by this paper
• EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

  2017cited by this paper
• Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer

  2017cited by this paper
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

  2017cited by this paper
• Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era.

  2017cited by this paper
• Pulsatile Erlotinib in EGFR‐Positive Non–Small‐Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature

  2017cited by this paper
• Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

  2016cited by this paper
• Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy

  2015cited by this paper
• Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.

  2015cited by this paper
• Leptomeningeal metastases: a RANO proposal for response criteria

  2014cited by this paper
• Leptomeningeal Metastases

  2012cited by this paper
• Cerebrospinal fluid.

  1965cited by this paper

• Overall survival in patients with non-small cell lung cancer and leptomeningeal metastases: Data from the Dutch cancer Registry.

  2025cites this paper
• Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases

  2025cites this paper
• Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study

  2025cites this paper
• Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation

  2024cites this paper
• Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.

  2024cites this paper
• Treatment Advances in Lung Cancer with Leptomeningeal Metastasis.

  2024cites this paper
• Radiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors

  2023cites this paper
• Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship.

  2023cites this paper